Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study
Abstract
To examine changes in partially responsive anxiety symptoms utilizing adjunctive treatment with atomoxetine in the treatment of adult ADHD patients with comorbid partially responsive anxiety symptoms. Consenting adult patients (n=29) with confirmed diagnosis of generalized anxiety and comorbid attention deficit hyperactivity disorder (ADHD) participated in this open-label study. All patients had significant comorbid anxiety symptoms (HAM-A>7) and failed to respond to 8-week trials of selective serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs). All patients were treated with atomoxetine as adjunctive to SSRIs or to SNRIs and were followed for at least 12 weeks. The primary outcome measure was the Clinical Global Impression severity subscale. Other scales included the Hamilton Anxiety Scale (HAM-A), the adult ADHD Self-Report Scale (ASRS-v1.1) symptom checklist, and Sheehan's Disability Scale. Baseline measures prior to the treatment with atomoxetine were compared to those at 4, 8, and at 12 weeks of treatment. Monitoring for pulse, blood pressure, and weight changes was carried out at baseline and at end point. Twenty-seven patients (93%) completed this open-label study. There was significant resolution of symptoms of all outcome measures, including the symptoms of anxiety, as shown by changes from baseline in HAM-A, ASRS-v1.1, and CGI at 12 weeks (P<.001). Also, there was significant reduction in the disability score at 12 weeks. Patients comp…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Effective treatment of ADHD has been shown to improve comorbid disorders including SUD, bipolar disorder, depression, and anxiety disorders.
“Effective treatment of ADHD has been shown to improve comorbid disorders including SUD [69,95,132], bipolar disorder [17], depression [69], and anxiety disorders [114,133].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [133]
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,882 · see citing works
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · see citing works
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · see citing works
Validity of pilot Adult ADHD Self-Report Scale (ASRS) to rate adult ADHD symptoms
Adler, L. A., Spencer, T., Faraone, S. V., Kessler, R. C., Howes, M. J., Biederman, J., & Secnik, K. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600801077 · Cited by 677 · see citing works
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · see citing works
Biederman, J., Faraone, S. V., Spencer, T. J., Mick, E., Monuteaux, M. C., & Aleardi, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0403 · Cited by 565 · see citing works
McGough, J. J., Smalley, S. L., McCracken, J. T., YANG, M. H., Del’Homme, M., Lynn, D. E., & Loo, S. K. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.9.1621 · Cited by 398 · see citing works
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392 · see citing works
Effectiveness and Tolerability of Tomoxetine in Adults With Attention Deficit Hyperactivity Disorder
Spencer, T., Biederman, J., Wilens, T. E., Prince, J., Hatch, M., Jones, J. T., CRAWFORD, M. H., Faraone, S. V., & Seidman, L. J. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.693 · Cited by 336 · see citing works
Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence
Brown, R. T., Amler, R. W., Freeman, W. S., Perrin, J. M., Stein, M. T., Feldman, H. M., Pierce, K., & Wolraich, M. L. (2005) · PEDIATRICS · doi:10.1542/peds.2004-2560 · Cited by 331 · see citing works
Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD
Wilens, T. E., Biederman, J., Faraone, S. V., Martelon, M., Westerberg, D., & Spencer, T. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04785pur · Cited by 286 · see citing works
Kessler, R. C., Brandenburg, N. A., Lane, M. C., Roy‐Byrne, P., STANG, P. D., Stein, D. J., & Wïttchen, H. (2005) · Psychological Medicine · doi:10.1017/s0033291705004538 · Cited by 238 · see citing works
GELLER, D. A., Donnelly, C. L., López, F. A., Rubin, R. L., Newcorn, J. H., Sutton, V. K., Bakken, R., Paczkowski, M., Kelsey, D. K., & Sumner, C. R. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180ca8385 · Cited by 208 · see citing works
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J. (2003) · Drug Safety · doi:10.2165/00002018-200326100-00006 · Cited by 191 · see citing works
Impairment and quality of life in individuals with generalized anxiety disorder
Henning, E. R., Turk, C. L., Mennin, D. S., Fresco, D. M., & Heimberg, R. G. (2007) · Depression and Anxiety · doi:10.1002/da.20249 · Cited by 189 · see citing works
Remission versus response as the goal of therapy in ADHD: A new standard for the field?
Steele, M., Jensen, P. S., & Quinn, D. M. P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.006 · Cited by 174 · see citing works
Kratochvil, C. J., Newcorn, J. H., Arnold, L. E., Duesenberg, D., Emslie, G. J., Quintana, H., Sarkis, E. H., Wagner, K. D., Gao, H., & Michelson, D. (2005) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000169012.81536.38 · Cited by 152 · see citing works
Adler, L., Spencer, T., Brown, T. E., Holdnack, J., Saylor, K. E., Schuh, K., Trzepacz, P., Williams, D., & Kelsey, D. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e4a0 · Cited by 150 · see citing works
Ruscio, A. M., Chiu, W. T., Roy-Byrne, P., Stang, P. E., Stein, D. J., Wittchen, H.-U., & Kessler, R. C. (2007) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2006.10.004 · Cited by 145 · see citing works
Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale
McIntyre, R. S. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050786 · Cited by 142 · see citing works
Simpson, D., & Plosker, G. L. (2004) · Drugs · doi:10.2165/00003495-200464020-00005 · Cited by 108 · see citing works
Atomoxetine, a Novel Treatment for Attention‐Deficit—Hyperactivity Disorder
Christman, A. K., Fermo, J. D., & Markowitz, J. S. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.11.1020.36146 · Cited by 97 · see citing works
Kratochvil, C. J., Vaughan, B. S., Harrington, M. J., & Burke, W. J. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.7.1165 · Cited by 94 · see citing works
Atomoxetine and Adult Attention-Deficit/Hyperactivity Disorder: The Effects of Comorbidity
Spencer, T. J., Faraone, S. V., Michelson, D., Adler, L. A., Reimherr, F. W., Glatt, S. J., & Biederman, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0312 · Cited by 94 · cited 2× · see citing works
“Also, clinical response to atomoxetine was predicted by the presence of a lifetime comorbid diagnosis of depression or post-traumatic stress disorder at baseline (Spencer et al. 2006).”
BackgroundFunctional Outcomes in the Treatment of Adults With ADHD
Adler, L. A., Spencer, T. J., Levine, L. R., Ramsey, J. L., Tamura, R., Kelsey, D., Ball, S. G., Allen, A. J., & Biederman, J. (2008) · Journal of Attention Disorders · doi:10.1177/1087054707308490 · Cited by 93 · cited 1× · see citing works
“For example, in a placebocontrolled study, atomoxetine-treated patients showed significantly greater improvement than placebo-treated patients on the Adult ADHD Quality of Life (AAQoL) scale (Adler et al. 2008a, b).”
Long-Term, Open-Label Safety and Efficacy of Atomoxetine in Adults With ADHD
Adler, L. A., Spencer, T. J., Williams, D. W., Moore, R. J., & Michelson, D. (2008) · Journal of Attention Disorders · doi:10.1177/1087054708316250 · Cited by 89 · see citing works
Adler, L. A., Sutton, V. K., Moore, R. J., Dietrich, A. P., Reimherr, F. W., Sangal, R. B., Saylor, K. E., Secnik, K., Kelsey, D. K., & Allen, A. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239797.21826.70 · Cited by 79 · see citing works
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL)
Matza, L. S., Johnston, J. A., Faries, D. E., Malley, K. G., & Brod, M. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9254-9 · Cited by 69 · see citing works
Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial
Gadde, K. M., Yonish, G. M., Wagner, H. R., Foust, M. S., & Allison, D. B. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803223 · Cited by 56 · cited 2× · see citing works
“0001) over the 12-week period than the placebo (n = 14) group (Gadde et al. 2006).”
BackgroundA Randomized Controlled Trial of Atomoxetine in Generalized Social Anxiety Disorder
Ravindran, L. N., Kim, D. S., Letamendi, A. M., & Stein, M. B. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bf6303 · Cited by 55 · see citing works
Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
Vaughan, B. S., Fegert, J. M., & Kratochvil, C. J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902762873 · Cited by 49 · see citing works
Combination pharmacotherapy for adult ADHD
Adler, L., Reingold, L. S., Morrill, M., & Wilens, T. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0044-9 · Cited by 47 · see citing works
Escitalopram in the Long-term Treatment of Major Depressive Disorder
Wade, A. G., Despiégel, N., & Reines, E. H. (2006) · Annals of Clinical Psychiatry · doi:10.1080/10401230600614447 · Cited by 44 · see citing works
Schweizer, E. E. (1995) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30026-1 · Cited by 43 · see citing works
Dell’Agnello, G., Zuddas, A., Masi, G., Curatolo, P., Besana, D., & Rossi, A. (2009) · CNS Drugs · doi:10.2165/11314350-000000000-00000 · Cited by 25 · see citing works
Gabriel, A. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0025-z · Cited by 17 · see citing works
Self-citationBrunt, D. L. V., Johnson, J. A., Ye, W., Pohl, G. M., & O'Hara, N. N. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.3.230 · Cited by 14 · see citing works
Scott, N. G., Ripperger-Suhler, J. A., Rajab, M. H., & Kjar, D. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0104 · Cited by 13 · see citing works
Wïttchen, H., Kessler, R. C., Brandenburg, N. A., Lane, M. C., Roy‐Byrne, P., STANG, P. D., & Stein, D. J. (2006) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(06)70586-7 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · see citing works
“In separate open trials, adjunctive atomoxetine [1428] and adjunctive extended release mixed amphetamine salts [1429] significantly improved anxiety symptoms in patients with ADHD and GAD refractory to antidepressants alone.”
BackgroundAdult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732 · see citing works
ADHD and Anxiety: Clinical Significance and Treatment Implications
Reimherr, F. W., Marchant, B. K., Gift, T. E., & Steans, T. A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0859-6 · Cited by 113 · see citing works
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89 · see citing works
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58 · see citing works
“…Polkinghorn, Lerer, & Stahl, 2005; Deligiannidis & Rothschild, 2010; Van Ameringen, Mancini, Patterson, & Stein, 2009), 21 open‐label trials (Gabriel & Violato, 2011; Gabriel, 2010; George et al., 2008; Glue et al., 2017, 2018; Heldt et al., 2003; Heldt et al., 2006; Hoge et al., 2008;…”
Clemow, D. B., Bushe, C., Mancini, M., Ossipov, M. H., & Upadhyaya, H. P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s115707 · Cited by 59 · see citing works
A review of atomoxetine effects in young people with developmental disabilities
Aman, M. G., Smith, T. H., Arnold, L. E., Corbett-Dick, P., Tumuluru, R. V., Hollway, J. A., Hyman, S. L., Mendoza-Burcham, M., Pan, X. J., Mruzek, D. W., et al. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.03.006 · Cited by 53 · see citing works
Atomoxetine for hoarding disorder: A pre-clinical and clinical investigation
Grassi, G., Micheli, L., Mannelli, L. D. C., Compagno, E., Righi, L., Ghelardini, C., & Pallanti, S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.012 · Cited by 49 · see citing works
Fox, H. C., & Sinha, R. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00006-8 · Cited by 46 · see citing works
Hutchison, S. L., GHUMAN, J. K., Ghuman, H. S., Karpov, I. O., & Schuster, J. M. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316647686 · Cited by 41 · see citing works
Perugi, G., Pallucchini, A., Rizzato, S., Pinzone, V., & Rossi, P. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1618270 · Cited by 34 · see citing works
Griffiths, K. R., Leikauf, J. E., Tsang, T. W., Clarke, S., Hermens, D. F., Efron, D., Williams, L. M., & Kohn, M. R. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.03.009 · Cited by 29 · see citing works
Jager, A., Kanters, D., Geers, F. E., Buitelaar, J. K., Kozicz, T., & Glennon, J. C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00768 · Cited by 24 · see citing works
Pharmacological treatment of adult ADHD
Bitter, I., Angyalosi, A., & Czobor, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328356f87f · Cited by 18 · see citing works
Ravishankar, V., Chowdappa, S. V., Benegal, V., & Muralidharan, K. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.017 · Cited by 19 · see citing works
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder
Brancati, G. E., Magnesa, A., Acierno, D., Carli, M., Rosa, U. D., Froli, A., Gemignani, S., Ventura, L., Weiss, F., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370346 · Cited by 13 · see citing works
Non-Antidepressant Treatment of Generalized Anxiety Disorder
Zahreddine, N., & Richa, S. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990058 · Cited by 11 · see citing works
Shim, S.-H., Woo, Y., Kim, J. S., Heo, I. S., Yoon, H.-J., Sung, H., Lee, J., & Bahk, W. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.143 · Cited by 9 · see citing works
Attention deficit hyperactivity disorder in adults
Chutko, L. S., Surushkina, S. Y., Yakovenko, E. A., & Cherednichenko, D. V. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412402197 · Cited by 8 · see citing works
Effectiveness of Atomoxetine in the Treatment of Children With Encopresis
Türkoğlu, S., Bi̇lgi̇ç, A., & Uzun, N. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000369 · Cited by 6 · see citing works
Brancati, G. E., Dominicis, F. D., Petrucci, A., Pallucchini, A., Carli, M., Medda, P., Schiavi, E., Rossi, P. D., Vicari, S., & Perugi, G. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2168750 · Cited by 5 · see citing works
Attention Deficit Hyperactivity Disorder
Marco, P., Maddalena, M., Bertella, S., Gatti, E., & Nobile, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00164-x · Cited by 4 · see citing works
Tripodi, B., Carbone, M. G., Matarese, I., Rizzato, R., Rocca, F. D., Dominicis, F. D., & Callegari, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248848 · Cited by 5 · see citing works
Brancati, G. E., Rosa, U. D., Magnesa, A., Dominicis, F. D., Petrucci, A., Schiavi, E., Medda, P., Barbuti, M., & Perugi, G. (2025) · Brain Sciences · doi:10.3390/brainsci15020182 · Cited by 6 · see citing works
Attention Deficit Hyperactivity Disorder and Anxiety
Ilipilla, G. S., Pranckun, Z. D., Wernick, H. J., Unsal, G., & Elia, J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-51147-6.00003-x · Cited by 3 · see citing works
Oliva, F., Carezana, C., Nibbio, G., Bramante, S., Pomeri, A. P., & Maina, G. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000320 · Cited by 3 · see citing works
Behavioral Medical Epigenetics
Cox, O., & Lee, R. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00008-9 · Cited by 2 · see citing works
Neal, J., Kim, S. H., Katz, B., Kim, I. H., & Lee, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.614628 · Cited by 1 · see citing works
Behavioral medical epigenetics
Cox, O., & Lee, R. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00017-7
Attention Deficit Hyperactivity Disorder in Adults
Chutko, L. S., Surushkina, S. Y., Yakovenko, E. A., & Cherednichenko, D. V. (2024) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01643-5
- Authors
- Gabriel, A., & Violato, C.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Gabriel, Adel
- ORCID
- Violato, Claudio
- Venue
- ADHD Attention Deficit and Hyperactivity Disorders
- Published
- 2011-08-11
- Volume
- 3
- Issue
- 4
- Pages
- 319-326
- ISSN
- 1866-6116 (ISSN-L)
- 1866-6647
- OpenAlex
- W1989450351
- Cited by
- 30
- References
- 42
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 1 · 2014: 3 · 2013: 2 · 2012: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- ADHD Attention Deficit and Hyperactivity Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- atomoxetine, adult ADHD, generalized anxiety disorder, anxiety comorbidity, adjunctive therapy, selective serotonin reuptake inhibitors, noradrenergic reuptake inhibitors, treatment-resistant anxiety, disability
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Adult, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Body Weight, Drug Resistance, Drug Therapy, Combination, Female, Heart Rate, Humans, Male, Middle Aged, Propylamines, Psychiatric Status Rating Scales, Selective Serotonin Reuptake Inhibitors, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
